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Abstract
Background: Venous thromboembolism (VTE) is a common and severe complication during treatment of acute
lymphoblastic leukemia (ALL). An important cause is the intensive use of asparaginase. Prospective cohort studies in
which prophylactic low-molecular-weight heparin (LMWH) was used to prevent VTE showed lower VTE risk than in
historic control cohorts, with a negligible bleeding risk. However, the efficacy of thromboprophylaxis with LMWH
during ALL treatment has never been investigated in a randomized design. Here, we present the protocol of a
randomized controlled trial in which the efficacy and safety of thromboprophylaxis with high prophylactic dose
LMWH versus no thromboprophylaxis will be assessed in children treated for primary ALL with asparaginase.
Methods/Design: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-
weight heparin (TropicALL) is a multicenter, randomized controlled open-label trial conducted in the Netherlands. Patients
between 1 and 19 years of age with primary ALL, who are treated within the Dutch Childhood Oncology Group (DCOG)
ALL-11 or 12 study will be randomized to thromboprophylaxis with LMWH once daily, (dose of 85 IU/kg (intervention
arm A)), or to no thromboprophylaxis (arm B, standard of care) during asparaginase courses of ALL treatment. Primary
efficacy endpoint is symptomatic objectified VTE during ALL treatment; secondary efficacy endpoints are overall survival
and the composite of symptomatic and asymptomatic objectified VTE. Primary safety endpoints are major bleeding,
clinically relevant non-major bleeding and minor bleeding. A total of 324 patients will be included to obtain a relative risk
reduction of 75% with a power of 80%, using a two-sided test with significance level α = 0.05.
Discussion: This trial will be the first to assess efficacy and safety of thromboprophylaxis with LMWH during asparaginase
treatment for ALL in children in a randomized design.
Trail registration: Nederlands Trial Register NTR4707. Registered 30 July 2014.
Keywords: Acute lymphoblastic leukemia, Low molecular weight heparin, Venous thromboembolic disease,
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Background
Acute lymphoblastic leukemia (ALL) is the most com-
mon type of childhood cancer, representing a quarter of
all pediatric malignancies [1, 2]. Survival rates for child-
hood ALL have improved significantly over the past
decades, with a current 5-year survival of 86% [3, 4].
This is a result of substantial improvements in ALL
treatment with risk-based therapy, increased treatment
intensity and improved supportive care [5, 6].
Venous thromboembolism (VTE) is a frequent and se-
vere complication during ALL treatment. Reported inci-
dences of VTE during ALL treatment vary from 1 to 37%
[7]. In unpublished data of the most recent Dutch Child-
hood Oncology Group (DCOG) ALL study, the ALL-10,
incidence of symptomatic VTE was about 10% [3], but may
have been underreported as VTE events were not systemat-
ically registered. The majority of VTE during ALL treat-
ment are cerebral sinovenous thrombosis (CSVT) and
catheter-related deep-vein thrombosis (DVT) (35–43%) [7–
10]. CSVT can be severe and life-threatening [7, 8]. Re-
ported overall mortality of CSVT varies between 10 and
21%, however limited data are available [7, 11]. Long term
complications are common; more than 50% of patients with
CSVT suffer from persistent neurological or cognitive im-
pairments, and one fifth of patients has a reported poor
quality of life [12–15]. Although mortality is rare in other
types VTE such as (catheter-related) DVT, morbidity is fre-
quent with for instance post-thrombotic syndrome (PTS),
characterized by swelling, ulceration, pain and dilated col-
lateral veins of the affected limb due to hampered venous
flow, being frequently seen, with reported in up to 68% of
patients [16–19].
Risk factors for VTE in ALL patients are well de-
scribed but difficult to avoid. In particular, asparaginase
therapy, which is an important component of ALL ther-
apy, is considered to be a major risk factor for VTE as it
reduces levels of natural anticoagulant proteins. Con-
comitant administration of corticosteroids may amplify
this effect [7, 8, 20, 21]. In addition, a procoagulant state
at diagnosis, presence of central venous catheters
(CVCs), inherited prothrombotic defects and infections
contribute to the risk of VTE [7, 8, 20, 22].
VTE occurrence leads to suboptimal treatment of
ALL patients. In 68% of CSVT patients, therapy ad-
justments are necessary [11], which may lead to re-
duced survival rates [4]. In addition, CVC-related
DVT is associated with recurrent catheter complications,
such as obstruction of the catheter and catheter-related
infections [23].
Currently, there are no evidence-based strategies to
prevent VTE complications during ALL treatment.
Administration of fresh frozen plasma (FFP) or anti-
thrombin (AT) do not reduce the risk of VTE [24]. A
few prospective cohort studies have been published
which use low-molecular-weight heparin (LMWH) for
thromboprophylaxis during ALL treatment. Elhasid et
al. reported on 41 children with ALL who received
LMWH prophylaxis during 4 to 8 courses in18–
24 days of L-asparaginase treatment. During 76
courses of asparaginase, none of the children devel-
oped VTE and no bleeding episodes occurred [25].
Mitchell et al. described 19 children with ALL and
increased risk for thrombosis, based on a VTE-risk
score, including asparaginase, steroids, presence of
CVC and thrombophilia. VTE developed in 1 of 8
children who were given prophylactic dose LMWH
and in 8 of 11 children without thromboprophylaxis.
No bleeding events occurred [26].
However, thromboprophylaxis with LMWH during ALL
treatment has not been studied in a randomized design.
As the prospective cohort studies showed promising re-
sults with a negligible bleeding risk, a large randomized
controlled trial is needed to confirm these findings.
Methods
Aim and study design
The TropicALL study is a multicenter randomized con-
trolled open-label trial conducted in the Netherlands. The
aim of this study is to assess the efficacy and safety of
thromboprophylaxis with LMWH in children treated for
primary ALL in the DCOG ALL-11 or subsequent study.
As a secondary objective, clinical risk factors will be evalu-
ated to increase insight in the pathogenesis of VTE during
ALL treatment and to establish a risk model for these
complications. In addition, since a thrombophilic state is
associated with a higher VTE risk, specific coagulation
assays, including antithrombin, fibrinogen, D-dimer,
thrombin antithrombin complex (TAT) and thrombin
generation, and genetic thrombophilic mutations Factor V
Leiden and prothrombin G20210A will be performed in
patients with and without VTE. The inclusion period is
3 years with a follow-up of 3 months after the end of the
ALL treatment period, or until recurrence of ALL, or until
death. Primary efficacy endpoint is the incidence of symp-
tomatic objectified VTE during ALL treatment; secondary
efficacy endpoints are incidence of the composite of symp-
tomatic and asymptomatic objectified VTE, and the value
of plasma coagulation assays to predict the risk of VTE.
Primary safety endpoint is major bleeding. Secondary
safety endpoints are the incidence of clinically relevant
non-major bleeding and minor bleeding, the burden of
LMWH injections, and adverse skin reactions.
Patients will be closely monitored for adverse events
during the study. All serious adverse events and unex-
pected adverse reactions, will be reported through the
web portal ToetsingOnline to the accredited Ethics
Committee that approved the study protocol. Further-
more a Data Monitoring Committee will semi-annually
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review all incidences of adverse events, symptomatic
VTE and bleeding complications. To enhance safety of
the study, DMC will provide the core committee with
recommendations related to the protection of the pa-
tients’ safety, including stopping recruitment and study
treatment.
Definitions
Symptomatic VTE is defined as suspicion of VTE based
on clinical symptoms, for instance for (CVC-associated)
DVT: peripheral deep vein thrombosis, swelling, ery-
thema, skin discoloration, increased warmth, pain, ten-
derness, venous distension, or presence of subcutaneous
collateral veins and objectively confirmed by imaging
tests. Other forms of VTE (i.e. pulmonary emboli and
CSVT) are defined as symptomatic venous thrombosis
in any component of the venous or pulmonary arterial
circulations or the heart, or the cerebral sinovenous
system, requiring therapeutic anticoagulation, acute
intervention, life-saving measures, ALL treatment adjust-
ments, or of fatal nature, and objectively confirmed by
routine imaging tests. Screening for asymptomatic VTE
should not be performed. However, if thrombi are inci-
dentally found upon diagnostic imaging for other in-
dications, these are counted as asymptomatic VTE.
Treatment of these asymptomatic VTE will be deter-
mined by the attending physician.
Bleeding is categorized as major, clinically relevant
non-major or minor bleeding according to Perinatal
and Pediatric Subcommittee of the Scientific and
Standardization Committee of the International Society
on Thrombosis and Haemostasis criteria [27]. A bleed-
ing is considered as major if it is a fatal bleeding, clinic-
ally overt bleeding associated with a decrease in
hemoglobin of at least 3.1 mmol/l in a 24-h period,
bleeding that is retroperitoneal, pulmonary, intracra-
nial, or otherwise involves the central nervous system;
and bleeding that requires surgical intervention in an
operating suite. A clinical relevant non-major bleeding
is defined as an overt bleeding for which a blood prod-
uct is administered and not directly attributable to the
patient’s underlying medical condition or a bleeding
that requires medical or surgical intervention to restore
hemostasis, not in an operating suite. All other overt
bleedings or macroscopic evidence of bleeding are con-
sidered minor.
Burden of LMWH injections is estimated by a visual
analogue scale (VAS) score and defined as a VAS
score > 5.
Study population
Children between 1 and 19 years of age with primary
ALL, who are treated within the DCOG ALL-11 or sub-
sequent study, are eligible for the TropicALL. Patients
will be excluded if they are already using anticoagulant
therapy upon screening, if they have active bleeding or a
high risk for bleeding contraindicating anticoagulant
therapy, including renal insufficiency (glomerular fil-
tration rate (GFR) < 30 ml/min/1.73 m2), hepatic
disease associated with coagulopathy leading to a clin-
ically relevant bleeding risk, stage 2 hypertension de-
fined as blood pressure confirmed >99th percentile
+5 mmHg, if they have a heparin allergy or a history
of heparin-induced thrombocytopenia (HIT), or any
other condition that, judged by the investigator, would
place the patient at increased risk of harm due to
participation. Thrombocytopenia is no exclusion cri-
teria. However, LWMH should be temporarily inter-
rupted, if platelet levels drop below 20 × 109/L.
ALL-11 study design
All patients in ALL-11 are treated with a standardized
treatment schedule. (Figs. 1, 2a and b.) All patients start
with Induction IA and IB, after which patients are strati-
fied according to their risk group. After risk group strati-
fication, patients with Standard Risk ALL will be treated
with cycle M, followed by cycle IV and maintenance
therapy. Medium Risk group patients will be treated
with cycle M, followed by Medium Risk Intensification
and maintenance cycles. High Risk group patients will
be treated with cycle M if identified by minimal residual
disease (MRD) or with High Risk blocks if identified
earlier. After three High Risk blocks, patients will
undergo assessment for allogeneic stem cell transplant-
ation eligibility, or will continue High Risk blocks. PEG-
asparaginase is included in Induction IA (day 12, 26, 4;
1500 IU/m2) and, in case of continuous asparaginase
treatment, IB (day 54, 68; individualized dose) and M
(day 9, 23, 37, 51; individualized dose). In Medium Risk
group patients (70% of all patients), PEG-asparaginase is
administered every 2 weeks for 14 times or 8 times dur-
ing Intensification, depending on the randomization
between standard and continuous asparaginase treat-
ment. Both arms have the same number of total PEG-
asparaginase administrations.
Intervention; LMWH regimen
LMWH (nadroparin) will be given subcutaneously once
daily, in a standardized prophylactic weight- and anti-Xa
adjusted dose of 85 IU/kg with a maximum of 5700 IU/
day [28]. Previous studies have indicated that especially
young children require higher dosages of LMWH.
Hence, peak anti-Xa levels should be measured, 3 to
5 days after start of LMWH prophylaxis, with an aimed
anti-Xa level of 0.3–0.4 IU/ml [29]. Lidocain/prilocain
cream can be applied to the skin locally for anesthesia
before each subcutaneous injection. If nadroparin is not
tolerated, other LMWHs can be administered according
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to local availability (Table 1). A registration booklet
and registration of unused drugs will be used to moni-
tor treatment compliance. The booklets will also in-
clude questions on the burden of daily subcutaneous
injections.
Data and blood sample collection
At the time of randomization for the TropicALL study
and during the study, data will be collected from all pa-
tients, including baseline data, clinical risk factors for
VTE, CVC characteristics, number of episodes of septi-
cemia, asparaginase therapy and administration of other
medications during ALL treatment.
Upon inclusion, one EDTA blood sample will be col-
lected for evaluation of genetic thrombophilic mutations
Factor V Leiden and Factor II mutation. Blood samples
for coagulation assays, including antithrombin, fibrino-
gen, D-dimer, thrombin antithrombin complex (TAT)
and thrombin generation, will be collected upon, during
the induction cycle before the 2nd and 3rd asparaginase
administration, and in Medium Risk group children in
week 1 of Intensification and on the last day of PEG-
asparaginase therapy of Maintenance. All coagulation as-
says will be performed at the end of the study. Blood
collection dates coincide with other set sample collec-
tion dates in ALL-11 or subsequent study and will not
form an extra burden for patients.
Sample size calculation
Power calculations were based on an estimated symp-
tomatic VTE incidence of 10% based on the previous
DCOG ALL-10 study, and an estimated relative risk re-
duction (RRR) of 75% based on the abovementioned co-
hort studies with LMWH in childhood ALL [25, 26, 30,
31]. Using nQuery Advisor (7.0, 2007), it was calculated
that 162 patients are required in each arm for a power
of 80%, using a two-sided test with significance level
α = 0.05. Hence, 324 patients will be randomized in this
study.
Randomization
Patients will be randomized to thromboprophylaxis with
LMWH (arm A) or to no thromboprophylaxis (arm B,
standard of care). Randomization will take place on day
11, which is the last day before the start of PEG-
asparaginase administration during the induction cycle.
A register of all patients, who were eligible but not in-
cluded in the study, will be kept and reason for refusal
of participation will be recorded. Randomization of
each patient will be performed by a randomization
computer program at the DCOG trial office and will be
stratified to ensure equal distribution of patients over
study arms. Stratification will be done according to type
of ALL (B-cell or T-cell) and study center. The proced-
ure will also guarantee concealment of allocation by the
treating physician.
Fig. 1 LMWH randomization in DCOG Protocol ALL 11, protocol 1A and 1B
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Treatment arms in TropicALL
All patients randomized to arm A will receive LMWH
from the day asparaginase is started, until 28 days (for
PEG-asparaginase) after the end of asparaginase therapy,
in all treatment cycles with asparaginase (Induction
cycle, Intensification in Medium Risk protocol). In case
PEG-asparaginase is replaced by Erwinia asparaginase,
LMWH will be given until 7 days after the last adminis-
tration of Erwinia asparaginase. Patients treated accord-
ing the medium risk arm of the protocol will receive
Fig. 2 a LMWH randomization in DCOG Protocol ALL 11, MR intensification, without anthracyclines. b LMWH randomization in DCOG Protocol
ALL 11, MR intensification, with anthracyclines
Table 1 Alternative LMWH schedule
LMWH Dose
Enoxaparin 1 – 18y: 1 mg/kg once daily s.c
Dalteparin 65 ± 21.5 IE/kg once daily s.c
Tinzaparin 1 – 5y: 120 IE/kg once daily s.c.
5 – 10y: 100 IE/kg once daily s.c.
10 - 18y: 87.5 IE/kg once daily s.c.
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34 weeks (=238 days) of LMWH in the induction and
intensification cycles, while patients treated according to
the standard risk and high risk ALL-11 protocols will
receive LMWH in the induction cycle only (=42 days
during and after asparaginase). Patients in arm B, the
standard of care arm, will not receive any form of
thromboprophylaxis.
LMWH should be stopped 24 h before interventions,
i.e. lumbar puncture or CVC insertion, and should be
restarted after invasive procedures or surgical interven-
tions within 24 h, provided the clinical situation allows.
Moreover, LMWH should be temporarily interrupted if
platelet levels drop below 20 × 109/L, and in case of
major bleeding.
Safety measures
If major bleeding occurs, the following measures should
be considered: (1) delay the next LMWH administration
or discontinue treatment, (2) consider protamine sulfate
administration, (3) consider usual treatment for bleed-
ing, including blood transfusion, and/or fresh frozen
plasma, (4) measure anti-Xa level of LMWH. If bleeding
cannot be controlled, consider administration of recom-
binant factor VII (Novoseven®) or prothrombin complex
concentrate.
Reporting of symptomatic VTE events
Patients are monitored for clinical symptoms of VTE
during all treatment cycles of ALL-11 and a 3-month
follow-up period. To establish systematic registration of
symptomatic VTE, events must be prospectively cen-
trally recorded on special VTE reporting forms in the
CRF. VTE reporting forms include several specifications
of the VTE to enable complete analysis of the event and
its consequences for the patient and ALL treatment. For
each symptomatic, objectively diagnosed VTE event in a
study patient, a VTE reporting form should be com-
pleted and returned to the DCOG Office within 14 days
after the event. Recurrent VTE should also be recorded.
Presence, replacement, removal or reinsertion of a
CVC should be documented in the CRF, as well as the
applied method of catheter flushing.
Statistical analysis
All data will be analyzed according to the intention-to-
treat principle. Descriptive data will be presented as mean
with its corresponding standard deviation if normally
distributed, and medians with ranges if data are skewed.
Depending on the data distribution the Student’s t test
or a Mann-Whitney U-test will be used to compare
continuous variables between the treatment groups.
Categorical variables will be analyzed using the Chi-
square test.
Efficacy and safety of LMWH to prevent VTE will be
analyzed by the difference between the incidence pro-
portions and cumulative incidences of the primary effi-
cacy and safety outcomes, symptomatic objectified VTE
and major or clinically relevant non-major bleeding, re-
spectively, observed from randomization up to 14 and
7 days after the last PEG asparaginase and Erwinia
asparaginase, respectively. A two-sided test with signifi-
cance level α = 0.05 will be used.
All bleeding events that occur during LMWH or
within 2 days after cessation of LMWH will be included.
Incidence proportions (number of children with out-
come during the period divided by number of children
at risk at the beginning of the period) and cumulative in-
cidences will be estimated by a joint model to estimate
event free survival for the primary safety outcome. To
identify which risks factors are associated with time to
VTE a joint model for longitudinal data and survival
outcome will be used.
Ethical considerations
The study has been approved by the Ethics Committee of
the Erasmus Medical Center in Rotterdam, the Netherlands,
and the local Ethics Committee of each participating hos-
pital. Patients can only be included in this study after
obtaining written informed consent of both parents and
children aged 12 and older. Verbal and written information
on all parts of the study should be given.
We acknowledge, daily subcutaneous injections for the
entire duration of asparaginase therapy could be a
burden for patients. However, the high risk of VTE and
potentially severe complications deriving from this VTE,
transcend potential burden of dialy injections. Lidocain/
prilocain cream will be applied to diminish the pain of
subcutaneous injections. To evaluate the burden, pa-
tients will receive a booklet with questions.
Withdrawal of patients
Children can discontinue their participation in the study
at any time for any reason if they wish to do so without
any consequences for their care, at their own request or
at the request of their parents/legally acceptable repre-
sentative. Furthermore, study medication can be stopped
prematurely in case of serious adverse events, VTE
requiring therapeutic anticoagulant treatment, or if, in
the investigator’s opinion, study medication should be
stopped for any other reason.
Discussion
Despite the fact that thromboprophylaxis with LMWH
has been proven to be safe in children for the prevention
of VTE, there are no randomized studies that have in-
vestigated the use of thromboprophylaxis with LMWH
during ALL treatment [32]. The TropicALL will be the
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first randomized controlled trial to investigate the safety
and efficacy of LMWH as thromboprophylaxis in children
treated for primary ALL. As a result of its incorporation
in the DCOG ALL-11 and subsequent study protocols,
optimal enrolment of patients is secured as well as imple-
mentation in all involved pediatric oncology centers. With
the results of this study, we intend to establish (inter)-
national guidelines with recommendations for thrombo-
prophylaxis during childhood ALL treatment.
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